Healthcare provider profile · identity verified

Timothy J Mccann, MD

Internal Medicine · SAINT LOUIS, MO · NPI 1538147491

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	902	210
Atorvastatin Calcium	Atorvastatin Calcium	667	180
Albuterol Sulfate Hfa	Albuterol Sulfate	464	88
Metformin Hcl	Metformin Hcl	354	83
Losartan Potassium	Losartan Potassium	313	90
Lisinopril	Lisinopril	291	78
Gabapentin	Gabapentin	283	53
Carvedilol	Carvedilol	227	54
Omeprazole	Omeprazole	204	52
Famotidine	Famotidine	189	29
Levothyroxine Sodium	Levothyroxine Sodium	176	37
Potassium Chloride	Potassium Chloride	173	37
Fluticasone Propionate	Fluticasone Propionate	161	35
Glipizide	Glipizide	153	36
Hydrochlorothiazide	Hydrochlorothiazide	149	35
Nifedipine Er	Nifedipine	143	26
Pantoprazole Sodium	Pantoprazole Sodium	132	20
Meloxicam	Meloxicam	118	16
Naproxen	Naproxen	118	19
Allopurinol	Allopurinol	111	21
Furosemide	Furosemide	107	27
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	104	17
Pravastatin Sodium	Pravastatin Sodium	98	24
Metoprolol Tartrate	Metoprolol Tartrate	97	22
Tamsulosin Hcl	Tamsulosin Hcl	92	25
Metoprolol Succinate	Metoprolol Succinate	90	24
Simvastatin	Simvastatin	85	29
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	85	14
Trazodone Hcl	Trazodone Hcl	84	suppressed
Spironolactone	Spironolactone	81	16
Ibuprofen	Ibuprofen	80	17
Eliquis	Apixaban	79	14
Jardiance	Empagliflozin	76	14
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	76	21
Hydroxyzine Hcl	Hydroxyzine Hcl	74	18
Lovastatin	Lovastatin	70	19
Symbicort	Budesonide/Formoterol Fumarate	68	17
Rosuvastatin Calcium	Rosuvastatin Calcium	65	17
Clopidogrel	Clopidogrel Bisulfate	61	18
Prednisone	Prednisone	55	suppressed
Ventolin Hfa	Albuterol Sulfate	55	18
Isosorbide Mononitrate Er	Isosorbide Mononitrate	54	suppressed
Januvia	Sitagliptin Phosphate	53	suppressed
Trulicity	Dulaglutide	53	13
Doxycycline Hyclate	Doxycycline Hyclate	52	45
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	51	14
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	50	16
Chlorthalidone	Chlorthalidone	49	suppressed
Diclofenac Sodium	Diclofenac Sodium	46	suppressed
Baclofen	Baclofen	43	suppressed
Sertraline Hcl	Sertraline Hcl	42	suppressed
Dulera	Mometasone/Formoterol	38	suppressed
Xarelto	Rivaroxaban	38	suppressed
Montelukast Sodium	Montelukast Sodium	37	11
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	37	suppressed
Clotrimazole	Clotrimazole	35	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	34	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	34	15
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	33	suppressed
Citalopram Hbr	Citalopram Hydrobromide	31	suppressed
Duloxetine Hcl	Duloxetine Hcl	29	suppressed
Farxiga	Dapagliflozin Propanediol	29	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	28	suppressed
Spiriva Handihaler	Tiotropium Bromide	28	suppressed
Hydralazine Hcl	Hydralazine Hcl	26	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	26	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	25	suppressed
Finasteride	Finasteride	23	suppressed
Humalog Kwikpen U-100	Insulin Lispro	23	suppressed
Atenolol	Atenolol	22	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	22	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	22	suppressed
Acyclovir	Acyclovir	21	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	21	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	21	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	20	suppressed
Breo Ellipta	Fluticasone/Vilanterol	19	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	15
Incruse Ellipta	Umeclidinium Bromide	19	suppressed
Calcitriol	Calcitriol	18	suppressed
Folic Acid	Folic Acid	18	suppressed
Meclizine Hcl	Meclizine Hcl	17	suppressed
Nyamyc	Nystatin	17	suppressed
Tradjenta	Linagliptin	17	suppressed
Fenofibrate	Fenofibrate	16	suppressed
Novolog Flexpen	Insulin Aspart	16	suppressed
Amoxicillin	Amoxicillin	15	11
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Alendronate Sodium	Alendronate Sodium	14	suppressed
Clonidine Hcl	Clonidine Hcl	14	suppressed
Glimepiride	Glimepiride	14	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	14	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	14	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	14	suppressed
Terazosin Hcl	Terazosin Hcl	14	suppressed
Valacyclovir	Valacyclovir Hcl	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	13	suppressed
Entresto	Sacubitril/Valsartan	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Sulfasalazine	Sulfasalazine	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Linzess	Linaclotide	12	suppressed
Niacin Er	Niacin	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	suppressed
Breyna	Budesonide/Formoterol Fumarate	11	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error